US › Healthcare

Mereo BioPharma Group PLC ADR (MREO)

US · Healthcare · Biotechnology

$0.29+9.06%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Revenue YoY

-100.0%

Net profit

$-7.0M

EPS

$-0.01

EPS estimate

$-0.01

EPS came in at -0.01 against a street estimate of -0.01 — a beat of 0.0%.

Key statistics

Market cap

$39.1M

Forward P/E

0.0

P/B

1.35

Book value

$0.18

EPS (TTM)

$-0.20

52-week high

$2.37

52-week low

$0.20

50-day MA

$0.30

200-day MA

$0.56

Beta

0.27

Analyst view

Analysts rate Mereo BioPharma Group PLC ADR a strong buy (8 buy, 0 hold, 0 sell out of 8) with an average price target of $1.99.

Shareholding

Insiders

0.75%

Institutions

36.09%

Largest institutional holders

Fund	Stake
Rubric Capital Management LP	9.59%
683 Capital Management LLC	7.51%
Bank of America Corp	5.13%
Defilade Capital Management, L.P.	4.73%
Newtyn Management LLC	4.43%
Tejara Capital Ltd	1.28%
UBS Group AG	0.93%
EcoR1 Capital, LLC	0.63%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Mereo BioPharma Group PLC ADR — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.